GlassScriptPhysician profile
Shellie D Hardcastle
NPI 1033111901
$14,968.70
in general payments reported to CMS, 2019-2025
74 companies · $4,132 in 2025
The $4,132 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,519 · 2022: $2,837 · 2023: $2,632 · 2024: $2,849 · 2025: $4,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,209 · Long Term Medical Supply Or Device Loan: $964 · Education: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,209.26 |
| Long Term Medical Supply Or Device Loan | $964.26 |
| Education | $438.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,376.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,169.10 | 2021-2025 | Enhertu, Datroway, Imfinzi |
| Janssen Biotech, INC. | $1,005.40 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Pfizer INC. | $802.64 | 2021-2025 | |
| Seagen INC. | $758.62 | 2021-2025 | Adcetris, Tukysa, Padcev |
| Daiichi Sankyo INC. | $741.57 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $561.49 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $530.75 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $449.16 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $398.56 | 2021-2025 | Tecentriq, Phesgo, Venclexta |
| Genzyme Corporation | $322.84 | 2021-2025 | |
| Gilead Sciences, INC. | $311.72 | 2021-2025 | Trodelvy |
| Exelixis INC. | $297.62 | 2021-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $281.87 | 2023-2025 | Libtayo, Lynozyfic |
| Abbvie INC. | $280.46 | 2022-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $248.87 | 2021-2025 | Ultomiris |
| Incyte Corporation | $248.39 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $233.79 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $221.93 | 2021-2023 | Lumakras |
| Beigene USA, INC. | $184.26 | 2024-2025 | Brukinsa, Tevimbra |
| Coherus Oncology, INC. | $172.80 | 2021-2024 | |
| Lilly USA, LLC | $166.24 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $162.78 | 2021-2025 | |
| Angiodynamics, INC. | $141.40 | 2023-2024 | Solero |
| Aveo Pharmaceuticals, INC. | $139.86 | 2021-2025 | Fotivda |
| Progenics Pharmaceuticals, INC. | $139.34 | 2024-2025 | |
| Taiho Oncology, INC. | $130.90 | 2021-2025 | |
| Beone Medicines USA, INC. | $126.37 | 2025 | Tevimbra, Brukinsa |
| Astellas Pharma US INC | $123.71 | 2021-2025 | Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $111.17 | 2022-2025 | Fruzaqla, Iclusig, Alunbrig |
| Stemline Therapeutics INC. | $104.80 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $97.19 | 2023-2025 | Epkinly, Tivdak |
| Array Biopharma INC | $94.40 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $93.90 | 2021-2023 | |
| Emd Serono, INC. | $91.31 | 2021-2025 | Bavencio |
| Adc Therapeutics America, INC. | $90.96 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $87.14 | 2021-2024 | Monoferric, Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.21 | 2021-2024 | Gilotrif |
| Karyopharm Therapeutics INC. | $85.23 | 2021-2024 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $81.13 | 2021-2025 | Onivyde, Tazverik |
| Rigel Pharmaceuticals, INC. | $78.59 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmaessentia USA Corporation | $77.65 | 2022-2025 | Besremi |
| Geron Corporation | $73.86 | 2025 | Rytelo |
| Sobi, INC | $61.54 | 2022-2024 | |
| Kyowa Kirin, INC. | $59.84 | 2021-2023 | Poteligeo |
| Blueprint Medicines Corporation | $59.64 | 2023-2024 | Ayvakit |
| Morphosys, US INC. | $57.46 | 2022-2023 | Monjuvi |
| Azurity Pharmaceuticals, INC. | $56.84 | 2025 | Danziten, Vivimusta |
| Tersera Therapeutics LLC | $56.16 | 2023-2024 | Zoladex |
| Global Blood Therapeutics, INC. | $51.52 | 2021-2022 | |
| Puma Biotechnology, INC. | $46.81 | 2021-2025 | |
| G1 Therapeutics, INC. | $43.50 | 2022 | |
| Mirati Therapeutics, INC. | $41.42 | 2024 | Krazati |
| Tg Therapeutics, INC. | $40.06 | 2021-2022 | |
| Glaxosmithkline, LLC. | $38.01 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Myovant Sciences INC. | $31.10 | 2022 | |
| Apellis Pharmaceuticals, INC. | $29.18 | 2022-2023 | Empaveli |
| Novocure INC. | $24.16 | 2023 | Optune |
| Dova Pharmaceuticals | $22.95 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.03 | 2024 | Givlaari |
| Accord Healthcare, INC. | $20.57 | 2025 | |
| Recordati_rare_diseases_inc. | $20.46 | 2023 | Sylvant |
| Aadi Bioscience, INC. | $19.99 | 2023 | Fyarro |
| Siemens Medical Solutions USA, INC. | $19.98 | 2022 | |
| Caris Mpi, INC. | $19.66 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $19.01 | 2024 | Orgovyx |
| Biocon Biologics INC | $17.99 | 2025 | Fulphila |
| Iovance Biotherapeutics, INC. | $17.97 | 2025 | Amtagvi |
| Acceleron Pharma, INC. | $17.33 | 2021 | |
| Daxor Corporation | $15.92 | 2024 | Bva-100 |
| Agios Pharmaceuticals, INC. | $14.91 | 2025 | Pyrukynd |
| Cti Biopharma Corp. | $14.88 | 2023 | Vonjo |
| Organon LLC | $13.16 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shellie Hardcastle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.